Neurosense Therapeutics Ltd Stock Price Prediction
| NRSNW Stock | USD 0.15 0.11 42.31% |
Oversold Vs Overbought
51
Oversold | Overbought |
Using NeuroSense Therapeutics hype-based prediction, you can estimate the value of NeuroSense Therapeutics Ltd from the perspective of NeuroSense Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in NeuroSense Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying NeuroSense because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
NeuroSense Therapeutics after-hype prediction price | USD 0.15 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
NeuroSense |
NeuroSense Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of NeuroSense Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in NeuroSense Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of NeuroSense Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
NeuroSense Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting NeuroSense Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on NeuroSense Therapeutics' historical news coverage. NeuroSense Therapeutics' after-hype downside and upside margins for the prediction period are 0.01 and 57.65, respectively. We have considered NeuroSense Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
NeuroSense Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of NeuroSense Therapeutics is based on 3 months time horizon.
NeuroSense Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as NeuroSense Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NeuroSense Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with NeuroSense Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
65.94 | 255.50 | 2.64 | 34.88 | 3 Events / Month | 9 Events / Month | In about 3 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.15 | 0.15 | 1.49 |
|
NeuroSense Therapeutics Hype Timeline
NeuroSense Therapeutics is now traded for 0.15. The entity has historical hype elasticity of 2.64, and average elasticity to hype of competition of -34.88. NeuroSense is estimated to increase in value after the next headline, with the price projected to jump to 0.15 or above. The average volatility of media hype impact on the company the price is over 100%. The price increase on the next news is projected to be 1.49%, whereas the daily expected return is now at 65.94%. The volatility of related hype on NeuroSense Therapeutics is about 48298.68%, with the expected price after the next announcement by competition of -34.73. Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. Assuming the 90 days horizon the next estimated press release will be in about 3 days. Check out NeuroSense Therapeutics Basic Forecasting Models to cross-verify your projections.NeuroSense Therapeutics Related Hype Analysis
Having access to credible news sources related to NeuroSense Therapeutics' direct competition is more important than ever and may enhance your ability to predict NeuroSense Therapeutics' future price movements. Getting to know how NeuroSense Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how NeuroSense Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| VALN | Valneva SE ADR | (0.06) | 4 per month | 0.00 | (0.44) | 3.20 | (5.86) | 12.07 | |
| DRUG | Bright Minds Biosciences | (9.63) | 9 per month | 4.62 | 0.14 | 9.23 | (11.87) | 1,471 | |
| HPQ | HP Inc | 0.51 | 9 per month | 1.62 | 0.02 | 2.22 | (2.63) | 6.13 | |
| INTC | Intel | (0.30) | 6 per month | 2.58 | 0.06 | 6.36 | (3.50) | 18.29 | |
| CVX | Chevron Corp | 1.42 | 6 per month | 1.05 | 0.02 | 2.21 | (1.79) | 5.13 | |
| KO | The Coca Cola | 0.69 | 8 per month | 0.00 | (0.30) | 1.11 | (1.66) | 4.00 | |
| TRV | The Travelers Companies | (0.41) | 7 per month | 1.17 | 0.09 | 1.93 | (2.17) | 11.31 | |
| JNJ | Johnson Johnson | 0.08 | 7 per month | 0.00 | (0.26) | 1.40 | (1.42) | 3.25 | |
| JPM | JPMorgan Chase Co | (2.36) | 8 per month | 1.42 | 0.05 | 2.05 | (2.00) | 15.87 | |
| MSFT | Microsoft | 4.77 | 8 per month | 1.49 | (0.05) | 2.09 | (1.85) | 8.19 |
NeuroSense Therapeutics Additional Predictive Modules
Most predictive techniques to examine NeuroSense price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for NeuroSense using various technical indicators. When you analyze NeuroSense charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About NeuroSense Therapeutics Predictive Indicators
The successful prediction of NeuroSense Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as NeuroSense Therapeutics Ltd, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of NeuroSense Therapeutics based on analysis of NeuroSense Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to NeuroSense Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to NeuroSense Therapeutics's related companies. | 2021 | 2023 | 2024 (projected) | Current Ratio | 19.12 | 0.84 | 0.8 | Net Debt To EBITDA | 3.2 | 0.23 | 0.22 |
Story Coverage note for NeuroSense Therapeutics
The number of cover stories for NeuroSense Therapeutics depends on current market conditions and NeuroSense Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that NeuroSense Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about NeuroSense Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
NeuroSense Therapeutics Short Properties
NeuroSense Therapeutics' future price predictability will typically decrease when NeuroSense Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of NeuroSense Therapeutics Ltd often depends not only on the future outlook of the potential NeuroSense Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NeuroSense Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 13.6 M | |
| Cash And Short Term Investments | 2.7 M |
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.